ArticleCancer science2026

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML.

Yuichiro Semba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.